Breaking News, Collaborations & Alliances

Samsung Bioepis, ATLATL Partner on Open Innovation Program

Aim to accelerate early-stage biotech innovation in Asia-Pacific.

Author Image

By: Charlie Sternberg

Associate Editor

Samsung Bioepis Co., Ltd. and ATLATL Innovation Center, global innovation platform for life science research and development, have entered a Memorandum of Understanding (MoU) for an open innovation program to accelerate early-stage biotech innovation in Asia-Pacific. Through this partnership, Samsung Bioepis aims to leverage ATLATL’s R&D network and expertise in the Asia-Pacific biotech sector to identify and support promising early-stage biotech companies and breakthrough technologies. ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters